INS and type 2 diabetes mellitus: 2,8,11 Adult and pediatric patients with T1D and adults with type 2 diabetes who were treated with faster aspart experienced improved postprandial glucose (PPG) control and similar or lower rates of hypoglycemia compared with IAsp.2,8,11 Moreover, the magnitude of improvements in PPG control with faster aspart versus IAsp are similar to those observed when earlier trials compared short-acting insulin analogs with regular human insulin.12,13 Faster aspart therefore represents an important addition to the available treatment options for T1D.